Published in Medical Letter on the CDC and FDA, August 8th, 2004
Included in the line are the Epic HF CRT-D and Atlas+ HF CRT-D, which received FDA approval earlier. The results of the V-V timing optimization phase of the RHYTHM (resynchronization hemodynamic treatment for heart failure management) ICD clinical trial serve as the basis for the submission.
The V-V Optimization phase of the trial studied the effects of V-V timing, the delay...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.